Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed FLT3 Mutated Acute MyEloid Leukemia Patients Treated With Gilteritinib in FrANCE

NCT05193448 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT05193448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05193448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed FLT3 Mutated Acute MyEloid Leukemia Patients Treated With Gilteritinib in FrANCE
Lead sponsor
French Innovative Leukemia Organisation
Phase
Observational
Overall status
Completed
Start date
July 5, 2021
Completion date
January 31, 2022
Enrollment
177 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

flt3-itd, flt3-tkd mutation, refractory aml, relapsed adult aml